[Featured Stock] Wooridul Hu Brain Rises on Collaboration with BBB for COVID-19 Diagnostic Kit

[Asia Economy Reporter Minwoo Lee] Wooridle Hubrain's stock price is on the rise. The diagnostic kit company VVV, a partner of Celltrion, is releasing a new coronavirus disease (COVID-19) diagnostic kit together, and the news that VVV is pursuing the acquisition of management rights of Syswork has highlighted Wooridle Hubrain's stake.

As of 2:15 PM on the 24th, Wooridle Hubrain's stock price was traded at 3,965 KRW, up 8.33% from the previous day. The news that it holds a 10.01% stake in VVV appears to have acted as a positive factor.

VVV, a diagnostic kit company partnered with Celltrion, plans to participate in a paid-in capital increase of 8.334 billion KRW by Syswork on the 4th of next month to acquire management rights. It is expected to achieve a backdoor listing through this.

As Wooridle Hubrain is strengthening cooperation by distributing VVV's severe brain disease treatment device 'Neurogear' and jointly developing COVID-19 diagnostic kits, expectations for cooperation among the three companies are growing.